Table 2.
Predictors of 30-day mortality in the study population
| Univariate |
Multivariate |
|||
|---|---|---|---|---|
| OR (95%CI) | P | OR (95%CI) | P | |
| Male sex |
2.03 (1.42-2.91) |
< .001d |
2.22 (1.43-1.64) |
< .001d |
| Age, y |
1.09 (1.07-1.11) |
< .001d |
1.1 (1.08-1.12) |
< .001d |
| CKD |
4.44 (2.59-7.64) |
< .001d |
||
| COPD |
2.22 (1.35-3.64) |
.002d |
||
| Diabetes |
2.82 (1.93-4.1) |
< .001d |
2.05 (1.27-3.29) |
.003d |
| Hypertension |
2.86 (1.99-4.09) |
< .001d |
||
| Smokinga |
1.55 (1.07-2.26) |
.021d |
||
| Previous heart disease |
2.26 (1.35-3.78) |
.002d |
||
| Statins |
1.13 (0.801-1.61) |
.479 |
0.48 (0.3-0.77) |
.002d |
| Aspirin |
2.35 (1.55-3.55) |
< .001d |
2.21 (1.26-3.87) |
.006d |
| RAAS inhibitorsb |
1.76 (1.2-2.58) |
.001d |
||
| Anticoagulantsc |
3.81 (2.45-5.93) |
< .001d |
1.98 (1.16-3.38) |
.013d |
| Beta-blockers |
2.79 (1.90-4.09) |
< .001d |
||
| Diuretics | 2.42 (1.55-3.79) | < .001d | ||
95%CI, 95% confidence interval; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; OR, odds ratio; RAAS, renin-angiotensin-aldosterone system inhibitors.
a
Includes active and former smokers.
b
Includes angiotensin converting enzyme inhibitors, angiotensin receptor blockers and spironolactone/eplerenone.
c
Vitamin K antagonist and new oral anticoagulants.
d
Significant P values.